日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

China starts latest trial of long-lasting HIV vaccine

By Wang Xiaodong | China Daily | Updated: 2019-07-19 07:30
Share
Share - WeChat
[Photo/VCG]

An HIV vaccine being developed by Chinese scientists will be given to 160 volunteers in a second-phase clinical trial, a medical scientist at the Chinese Center for Disease Control and Prevention said on Monday.

The candidate vaccine, DNA-rTV, relies on replication of the DNA of HIV to stimulate effective immunization, according to Shao Yiming, a chief HIV researcher at the center.

He said the vaccine, based on the one used to prevent smallpox, is the first such HIV vaccine to begin a second-phase clinical trial.

"With significant reduction of virulence, the vaccine will not cause infection in healthy receivers," Shao said.

The vaccine under development does not contain the full human immunodeficiency virus. Rather, it contains DNA segments from HIV so it will not cause an infection.

The HIV DNA will keep replicating during the initial period of injection of the vaccine, so it will constantly stimulate the immune system to produce antibodies, meaning the effect will be stronger and longer lasting. This is similar to how vaccines for some other diseases work.

Most of the other HIV vaccines under development in China and abroad are inactivated vaccines, which do not include HIV DNA that can replicate, so they will not produce a long-lasting immunization effect.

The vaccine is also designed to target the HIV strains that are most common in China, he said.

Its first-phase clinical trial, which started in 2007, proved its safety, Shao said. The second-phase trial will determine the vaccination procedure, he said.

Shao Yiming. [Photo/China Daily]

"Hopefully the second-phase trial will be completed in the latter half of 2021, and the third-phase clinical trial may start at the end of that year, which will involve thousands of volunteers in a trial to test the effectiveness of the vaccine to protect people against HIV," Shao said.

More than 130 volunteers have been recruited so far for the second-phase trial, and the initial work is underway at a hospital in Beijing and another hospital in Hangzhou, Zhejiang province, he said.

Chuang Chuang, who runs Hangzhou Sunflower, a charity organization promoting LGBT rights that helped recruit volunteers in Hangzhou, said more than 100 volunteers had approached the organization to register after hearing about the second-phase trial.

"Some of them were disqualified after our selection process, and the rest were referred to the hospital in Hangzhou," he said. "They must pass physical tests before formally becoming volunteers.

"Most of the volunteers I know are students or (other) young men. Some signed up initially, but withdrew after being informed they would have to participate the whole trial, which lasts nearly two years.

Nuan Yang, a volunteer from Hangzhou, said he registered through the organization as soon as he heard about the second-phase trial.

"I hope to see the vaccine available for us as early as possible. Although HIV can be controlled and AIDS is almost a chronic disease now, many people with HIV are living under heavy pressure and have to endure discrimination from others," he said.

"If a vaccine is available to prevent the infection, fewer people will fear HIV and discriminate against carriers."

Shao said developing HIV vaccines was much harder than developing vaccines for other diseases because of the constantly evolving nature of HIV, but progress has been made around the world in the past decade.

"AIDS is one of the most serious threats to human health, and we should never lose faith we will conquer it, even though it is very difficult," he said.

The number of people living with HIV in China was estimated at around 1.25 million at the end of last year, and about 80,000 people become infected each year, according to the National Health Commission.

Although the prevalence of HIV infection in China is lower than in many other countries, China faces severe challenges in prevention and control due to the large number of cases, it said.

Sustained efforts, including improved public education, are needed, the commission said.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 日韩欧美综合在线二区三区 | 欧美精品福利视频 | 狠狠干美女 | 欧美在线播放一区 | 黄色av免费看 | 欧洲精品在线观看 | 黄色资源视频 | 2021国产成人午夜精品 | www.av视频 | 日本va视频 | 奇米影视 首页 | 欧美成人午夜在线全部免费 | 91手机在线视频观看 | 麻豆changesxxx国产 | 大片一级 | 精品小视频| 碰碰碰精品视频在线观看 | 成人亚洲| 国产精品高潮呻吟久久av黑人 | 亚洲午夜精品国产电影在线观看 | 亚洲成人福利网站 | 91视频会员 | 婷婷久久无码欧美人妻 | 国产精品毛片久久久久久 | 国产高清精品在线 | 男女xx00xx的视频免费观看 | 在线a人片免费观看国产 | 狠狠色丁香婷婷综合橹不卡 | 欧美高清hd| 欧美一级h | 亚洲一二三区视频 | 国产精品一区二区三区在线播放 | 午夜精品一区二区三区免费视频 | a在线免费观看视频 | 久久久精品午夜免费不卡 | 啊啊啊网站 | 九九爱这里只有精品 | 亚洲欧美综合乱码精品成人网 | 国产喷水 | 国产成人综合在线观看网站 | 成年做羞羞免费观看视频网站 |